OTC Bulletin Board

S & P Company Insight for TRANSGENOMIC INC
 
 Profile

 
Business Summary: Transgenomic, Inc. provides products for the purification and analysis of nucleic acids used in the life sciences industry for research primarily on molecular genetics and diagnostics.
 
Address
  12325 Emmet Street
  Omaha , NE 68164
  Phone: 402-452-5400
  Fax: 402-452-5401
  Website: http://www.transgenomic.com
Transfer Agent
  Wells Fargo Shareowner Services
Employees:  103
ShareHolders:  2800
Founded:  1997
Domicile:  Delaware
 
  
 
 Background

 
Transgenomic, Inc. provides products for the purification and analysis of nucleic acids used in the life sciences industry for research focused on molecular genetics and diagnostics. It also provides genetic variation analytical services to the medical research, clinical and pharmaceutical markets. Net sales are categorized as Instrument Related Business and Laboratory Services. The Instrument Related Business comprises bioinstruments, including the company's flagship product, the WAVE System, and bioconsumables. The WAVE System has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. There was a worldwide installed base of over 1,475 WAVE Systems as of Mar. 31, 2010. Transgenomic also distributes bioinstruments produced by other manufacturers through its sales and distribution network. Service contracts to maintain installed systems are sold and supported by technical support personnel. The installed WAVE base and some third-party installed platforms generate a demand for consumables that are required for the continued operation of the bioinstruments. Transgenomic develops, manufactures and sells these consumable products. In addition, Transgenomic manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of HPLC separation columns. The company continues to seek emerging markets and novel applications to provide it with new opportunities for its WAVE System such as its newly launched K-RAS mutation detection kit. It also seeks opportunities to diversify into new markets, including the personalized medicine market (particularly in oncology). In addition, Transgenomic also sells refurbished WAVE Systems in order to provide an opportunity for customers that may not be able to afford the cost of a new system. Located in Omaha, Nebraska, the company's molecular clinical reference laboratory specializes in mitochondrial and molecular diagnostic testing including genetic testing for oncology, hematology and inherited disorders. In addition, pharmacogenomics research services are provided by the company's Contract Research Organization in Omaha, Nebraska. The Contract Research Organization specializes in pharmocogenomic, biomarker and mutation discovery research serving the pharmaceutical and biomedical industries for disease research, drug and diagnostic development and clinical trial support. The company was founded in 1997 and is based in Omaha, Nebraska.
History:  INCORPORATED in Delaware Mar. 6, 1997.
 
Subsidiaries:
Annovis, Inc.
Transgenomic Japan, Inc.
Transgenomic Limited
 
 
Capital Expenditures, thousand. US Dollars
  Year  Amount
  2009  351
  2008  325
  2007  720
 
Research and Development Expenditures, thousand. US Dollars
  Year  Amount
  2009  3,182
  2008  2,465
  2007  3,033
 
  
 
 Management

 

Management
OfficersPosition
 Rodney  MarkinChairman
 Brett L. FrevertChief Financial Officer
 Kim Sutton GolodetzInvestor Relations Contact

Directors
 Rodney  Markin
 Michael B. McNulty
 Antonius P. Schuh
 Jeffrey L. Sklar
 Greg T. Sloma
 
  
 
 Annual Report

 
Annual Report
 
Income Statement
  20092008
REVENUES
Net Sales22,02323,993
EXPENSES
Cost of Sales(10,418)(10,345)
Selling, General and Administrative(10,319)(10,795)
Research and Development(3,182)(2,465)
Goodwill Impairment Charges-(638)
Restructuring Charges-(118)
Interest Income1574
Other Income/expense312
Earnings before Taxes(1,878)(282)
TAXES AND OTHER EXPENSES
Provision for Income Tax(42)(213)
Net Income (Loss)(1,920)(495)
SUPPLEMENTARY INFO
Gross Profit/loss11,605.0013,648.00
Operating Income (Loss)(1,896.00)(368.00)
Basic EPS - Continuing Operations(0.04)(0.01)
Diluted EPS - Continuing Operations(0.04)(0.01)
 
Balance Sheet
  20092008
CURRENT ASSETS
Cash and Cash Equivalents5,6424,771
Accounts Receivables4,5225,385
Inventories3,5524,775
Prepaid Expenses and Other Current Assets738654
Total Current Assets14,45415,585
NON CURRENT ASSETS
Furniture, Fixtures and Leasehold Improvements3,8343,920
Equipment9,97210,059
Accumulated Depreciation(12,839)(12,781)
Other Assets583773
Total Assets16,00417,556
CURRENT LIABILITIES
Accounts Payable1,013905
Accrued Expenses2,5172,810
Accrued Compensation573520
Total Current Liabilities4,1034,235
NON CURRENT LIABILITIES
Other Long-term Liabilities239116
SHAREHOLDERS' EQUITY
Common Stock - Par Value497497
Additional Paid in Capital139,703139,501
Accumulated Deficit(130,183)(128,263)
Accumulated Other Comprehensive Income (Loss)1,6451,470
Total Shareholders Equity11,66213,205
Total Liabilities & Shareholders Equity16,00417,556
 
  
 
 Interim Report

 
Interim Report   
 
Data Not Available
 
 
 
 
  
 
 Pro Forma Report

 
Pro Forma Report   
 
Data Not Available
 
 
 
 
  
 
 Quarterly Report

 
Quarterly Report Information   
 
Quarterly Revenue, US$
YearQuarterRevenue
  2010   15,440,000
  2009   14,990,000
  2009   25,470,000
  2009   35,050,000
  2009   46,510,000
  2009   Full Year 22,020,000
  2008   16,250,000
  2008   26,250,000
  2008   35,370,000
  2008   46,130,000
  2008   Full Year 23,990,000
  2007   15,220,000
  2007   26,220,000
  2007   35,150,000
  2007   46,530,000
  2007   Full Year 23,180,000
  2006   16,500,000
  2006   26,190,000
  2006   34,920,000
  2006   45,810,000
  2006   Full Year 23,420,000
  2005   16,930,000
  2005   26,890,000
  2005   36,660,000
  2005   45,350,000
  2005   Full Year 25,830,000
 
 
Quarterly Net Income, US$
YearQuarterRevenue
  2010   1(320,000)
  2009   1(950,000)
  2009   2(730,000)
  2009   3(370,000)
  2009   4130,000
  2009   Full Year (1,920,000)
  2008   1120,000
  2008   2100,000
  2008   3(500,000)
  2008   4(220,000)
  2008   Full Year (500,000)
  2007   1(1,270,000)
  2007   2230,000
  2007   3(1,350,000)
  2007   4210,000
  2007   Full Year (2,170,000)
  2006   1(300,000)
  2006   2(260,000)
  2006   3(1,520,000)
  2006   4(880,000)
  2006   Full Year (2,960,000)
  2005   1(2,160,000)
  2005   2(470,000)
  2005   3(530,000)
  2005   4(1,820,000)
  2005   Full Year (4,984,000)
 
 
Quarterly EPS, US$
YearQuarterRevenue
  2010   1(.01)
  2009   1(.02)
  2009   2(.01)
  2009   3(.01)
  2009   4Nil
  2009   Full Year (.04)
  2008   1Nil
  2008   2Nil
  2008   3(.01)
  2008   4Nil
  2008   Full Year (.01)
  2007   1(.02)
  2007   2Nil
  2007   3(.03)
  2007   4Nil
  2007   Full Year (.04)
  2006   1(.01)
  2006   2(.01)
  2006   3(.03)
  2006   4(.02)
  2006   Full Year (.06)
  2005   1(.07)
  2005   2(.01)
  2005   3(.02)
  2005   4(.04)
  2005   Full Year (.14)
 
  
 
 Stock Data

 
 
Capitalization as of 03/31/2010:
 
 Authorized SharesOutstanding Shares
Preferred $0.01 par15,000,000None
Common $0.01 par100,000,00049,189,672
 
LONG TERM DEBT: None.
 
Common $0.01 par
 
COMMON OFFERED: July 18, 2000, the company, through underwriters led by Chase Securities Inc., Bear, Stearns & Co. Inc. and Dain Rauscher Inc., offered 4,480,000 Common shares at $15.00 per share; comm., $1.05 per share. An additional 672,000 were available to cover over-allotments.
 
Stockholders:  12/31/2009, 2800.
PRINCIPAL STOCKHOLDERS: March 22, 2010, LeRoy C. Kopp owned or controlled 26.0% of the Common, Barclays PLC 9.9%, AMH Equity, LLC 9.9% and Michael A. Roth and Brian J. Stark 6.7%.
 
Transfer Agent:  Wells Fargo Shareowner Services   South St. Paul , MN
 
OTC Bulletin Board( Primary): TBIO
 
ExchangeYearHighLow
OTC Bulletin Board20090.75000.2100
OTC Bulletin Board20080.87000.2400
OTC Bulletin Board200742.690026.5600
Nasdaq Capital Market20061.03000.3100
NASDAQ National Market20051.25000.3800
NASDAQ National Market20043.32001.0000
NASDAQ National Market20034.22000.9300
NASDAQ National Market200211.05001.5100
NASDAQ National Market200125.99005.1875
NASDAQ200030.01605.7500
 
DIVIDENDS: Common $0.01 par: None.